Clinical evaluation of subcutaneously administered DDAVP

Perioperative management of von Willebrand disease: a review for the anesthesiologist

“…The efficacy of perioperative desmopressin therapy was first shown in the 1980s and early 1990s in small clinical trials that included dental patients [29][30][31]. More recently, it has been evaluated in other groups of surgical patients ( Table 2).…”

Intranasal DDAVP: Biological and Clinical Evaluation in Mild Factor VIII Deficiency

“…The usefulness of the vasopressin ana logue DDAVP in the treatment of mild and moderate hemophilia A as well as von Willebrand's disease is well established [2,3].…”

“…In previously published case reports [2,3], the vasopressin analogue was given by intravenous or subcutaneous infusion. In our study, the drug was given by intranasal inhalation in the patients affected with mild factor VIII deficiency.…”

“…1 -Deamino-8-/9-arginine vasopressin (DDAVP), a synthetic vasopressin derivate, causes an increase of factor VIII:C/von Wil lebrand factor antigen in patients with mod erate or mild hemophilia A and von Willebrand's disease [1], These properties have been applied successfully in the prevention or treatment of bleeding episodes [2,3], Although it has been shown by sever al authors that intranasal application of DDAVP causes a dose-related release of fac tor VIII/von Willebrand factor antigen in healthy volunteers [4], there are only anecdotical reports on the efficacy of this way of administration in hemophiliacs [5,6], In these patients, in fact, the drug has been gen erally given by intravenous and/or subcuta neous routes [2,3], This study was under taken to test the biological effect of intra nasal DDAVP and its efficacy in the pre vention and therapy of bleeding complica tions in mild factor VIII deficiency.…”

Response to 1-Deamino-8-<i>D</i>-Arginine Vasopressin in von Willebrand Disease

“…Among 52 patients with vWD type I evaluat ed, the mean increase in vWF:Ag levels was 2.7 over baseline values [35]. In persons with mild vWD type I, SC DDAVP was found to be effective in preventing excessive bleeding during and following 10 tonsillectomies and 8 other surgical procedures [35], Ghirardini et al [36] used 0.3 gg/kg DDAVP given SC in 6 vWD patients during 4 surgical procedures and 4 spontaneous bleeding episodes with good results.…”